Key Takeaway

• Vertical Integration: McKesson already has experience in clinical care delivery through its acquisition of US Oncology in 2010 and its Canadian INVIVA infusion network. The Option Care acquisition expands its presence in U.S. home and alternate-site infusion services.

• Distribution vs. Care Delivery: Infusion services require nursing infrastructure, clinical operations, and patient access beyond pharmaceutical distribution. Execution risks remain in managing patient referrals and treatment administration.

• Private Equity(PE) Opportunity: CD&R’s investment points to continued PE interest in established healthcare services companies trading at discounted valuations

Strategic Rationale - McKesson

• Expand Specialty Infusion Services: Gain access to a national home and alternate-site infusion network serving over 315,000 patients across all 50 states, supported by more than 5,000 clinicians and established hospital, physician, and payer relationships.

• Broaden Specialty Care Capabilities: Expand into complex therapies for autoimmune, neurological, and rare diseases while supporting the shift from hospitals to lower-cost home and community-based care.

• Capture Commercial Synergies: Leverage McKesson’s purchasing power, pharmaceutical distribution infrastructure, and manufacturer relationships to improve drug procurement and support new specialty therapies. Evercore estimates $1.0–$1.5B in potential incremental distribution revenue and $10–$30M in adjusted operating income.

• Establish a Path to Full Ownership: Secure a framework to acquire CD&R’s remaining stake, subject to specified conditions and regulatory approvals.

Strategic Rationale – Option Care Health

• Deliver value to shareholders: Offers $32.05 per share in cash, approximately 37% above the October 5 closing price. Provides a cash exit amid earnings pressure and uncertainty over the company’s recovery.

• Continue under existing management: Keeps Option Care as a separate company with its own management team, with backing to invest in services and technology.

Expert Opinion on Transaction

• J.P. Morgan — Attractive purchase price: Values the deal at 11× expected 2027 adjusted EBITDA, viewing the price as modest given Option Care’s strategic value.

• William Blair — Recent problems explain the lower price: Notes that several similar home-based healthcare businesses sold at higher earnings multiples. Option Care’s patient losses and uncertain recovery help explain the difference. The buyers could benefit if the business improves.

• Evercore — Earnings and distribution upside: Estimates a 0.7% boost to McKesson’s fiscal 2028 earnings per share before operating benefits, assuming an April 2027 closing. Additional distribution business could generate $1.0–$1.5 billion in revenue and $10–$30 million in adjusted operating income.

• UBS — Limited early benefit: Expects McKesson’s first-year earnings to remain broadly unchanged or fall slightly before operating benefits, assuming 50% debt and 50% cash funding.

Option Care Health: Company Overview

Option Care Health (NASDAQ: OPCH) is the largest independent provider of home and alternate-site infusion services in the United States. The company provides specialty pharmaceutical therapies outside traditional hospital settings through an integrated network of pharmacies, infusion facilities, and more than 5,000 clinical professionals.

Business Model and Services

• Chronic Therapies (~75% of Revenue): Recurring infusion treatments for autoimmune diseases, immune deficiencies, neurological conditions, and rare disorders.

• Acute Therapies (~25% of Revenue): Short-term infusion treatments, primarily intravenous antibiotics for serious infections.

• Integrated Care Delivery: Combines pharmaceutical procurement, medication preparation, nursing services, treatment administration, patient monitoring, and insurance authorization.

• Reimbursement Model: Generates revenue through commercial insurers, government healthcare programs, and other payers under negotiated reimbursement arrangements.

Financial Performance

Competitive Positioning

• National operating scale, established hospital and physician referral relationships, and specialized clinical infrastructure.

• Its integrated pharmacy and nursing capabilities enable the administration of complex specialty therapies in patients’ homes and ambulatory infusion centers.

• Benefits from growing specialty pharmaceutical utilization and the continued migration of clinically appropriate infusion treatments from hospitals to lower-cost care settings.

See the detailed Report Below:

Read more

Strategic Rationale – Agilent’s Acquisition of Proscia

• End-to-End Pathology Integration: Combine Agilent’s staining instruments, reagents, and diagnostic assays with Proscia’s digital pathology and AI platform.

• Build on Biocare Acquisition: Extend Agilent’s $950M Biocare acquisition with digital image management and AI capabilities.

• Expand Market Reach: Cross-sell Proscia’s Concentriq software across Agilent’s established Dako customer base.

• Advance Precision Medicine: Integrate pathology data with biomarker research and companion diagnostics.

• Increase Recurring Revenue: Add subscription-based software revenue alongside existing instruments and consumables.

• Capture Digital Pathology Growth: Capitalize on increasing AI adoption and digital pathology penetration, currently estimated at 20–30%.

Management Commentary Relevant to the Transaction

Proscia Overview

Business Model

• Clinical SaaS: Annual subscriptions for digital pathology management, diagnostic review, and laboratory workflows.

• Life Sciences Software: Enterprise licensing for pharmaceutical companies and CROs conducting biomarker research and clinical trials.

• Data Solutions: Commercializes pathology datasets and patient insights for drug development and companion diagnostics.

Key Metrics

Product Overview

• Concentriq: FDA-cleared digital pathology software for slide management, AI-enabled analysis, and clinical diagnostics.

• Proscia Aperture: Real-world data platform integrating pathology images with clinical, molecular, and genomic information.

Agilent–Proscia Partnership

• Established Partnership: Four-year distribution relationship (2022–2026), preceding the acquisition.

• Clinical Adoption: Joint digital pathology deployment at South Bend Medical Foundation in January 2026.

• Commercialization & Integration: Concentriq offers 100+ laboratory information system integrations, while Proscia targeted 32,000 daily diagnostic cases by July 2025.

See the detailed Report Below

Read more

Neuromodulation Market Overview

Market Landscape

• Expanding Therapeutic Applications: Neuromodulation devices use targeted electrical, magnetic, or other forms of stimulation to treat chronic pain, movement disorders, epilepsy, depression, and pelvic health conditions. Emerging applications in inflammatory diseases and neurological rehabilitation are broadening the addressable market.

• Technological Innovation: Closed-loop stimulation, AI-enabled programming, miniaturized implants, and wireless connectivity are improving treatment personalization, procedural efficiency, and patient management.

• Favorable Demographic Trends: Aging populations, increasing prevalence of neurological disorders, and growing demand for non-pharmacological therapies are supporting long-term market adoption.

• Established Market Leadership: Medtronic, Abbott, and Boston Scientific maintain strong competitive positions through extensive product portfolios, physician relationships, clinical evidence, and established reimbursement infrastructure.

Market Size & Growth Outlook

• Global Market Expansion: The implantable neuromodulation and neuroprosthetics market was estimated at approximately $8.2 billion in 2025 and is projected to reach $13.5 billion by 2030, representing an 8.8% CAGR.

• Spinal Cord Stimulation (SCS): SCS remains the largest established pain-management segment, with an estimated global market of $2.3–$2.7 billion. Adaptive stimulation and closed-loop technologies are supporting continued innovation.

• Peripheral Nerve Stimulation (PNS): PNS is emerging as a high-growth segment, expanding at approximately 22% annually as minimally invasive, non-opioid pain-management alternatives gain traction.

• Regional Growth: North America remains a leading market, supported by established reimbursement and advanced healthcare infrastructure, while Asia-Pacific presents significant growth opportunities as access to neuromodulation therapies expands.

Evolution of Neuromodulation Technologies

Neuromodulation is progressing through three broad technology generations, with innovation increasingly focused on precision, automation, and accessibility.

Generation 1: Established Implantable Technologies

Traditional implantable platforms established neuromodulation as a commercially viable therapeutic category.

• Deep Brain Stimulation (DBS): Delivers electrical stimulation to targeted brain regions, primarily for movement disorders such as Parkinson’s disease.

• Spinal Cord Stimulation (SCS): Modulates spinal pain pathways to treat chronic neuropathic pain.

• Vagus Nerve Stimulation (VNS): Stimulates the vagus nerve for conditions including epilepsy and treatment-resistant depression.

• Sacral Neuromodulation (SNM): Targets sacral nerve pathways to manage bladder and bowel dysfunction.

These established platforms benefit from clinical validation and reimbursement pathways but require surgical implantation, specialized programming, and ongoing clinical support.

Generation 2: Next-Generation Implantables

The next technology cycle is shifting from fixed stimulation toward adaptive, sensing-enabled devices.

• Closed-Loop Stimulation: DBS and SCS platforms increasingly incorporate physiological sensing to automatically adjust stimulation based on patient responses.

• Miniaturized & Targeted Implants: Smaller devices, advanced electrode designs, and targeted PNS technologies are reducing hardware burden and enabling more localized therapy.

• Software-Driven Optimization: AI-enabled programming, remote monitoring, and automated therapy adjustments are reducing clinician workload and improving treatment personalization.

• Connected Care: Cloud-based platforms and wireless connectivity are extending therapy management beyond the initial implantation procedure.

Generation 3: Non-Invasive & Emerging Technologies

Non-invasive technologies are expanding neuromodulation beyond surgical procedures and specialized treatment centers.

• Transcranial Magnetic Stimulation (TMS): An established non-invasive treatment platform for depression and certain other neuropsychiatric disorders.

• Focused Ultrasound (FUS): Uses acoustic energy for targeted neurological interventions, with emerging applications in reversible neuromodulation.

• Transcutaneous Nerve Stimulation: External stimulation of peripheral or cranial nerves is enabling less-invasive approaches across pain management and neurological conditions.

• Wearable & At-Home Platforms: Portable stimulation devices and remotely supervised treatment models could expand access and reduce dependence on repeated clinic visits.

Neuromodulation Business Models

Established Implantable Platforms

• Implant-Driven Revenue: Manufacturers generate revenue primarily through implantable pulse generators, leads, and associated components sold during implantation procedures.

• Recurring Replacement Revenue: Battery replacements, device upgrades, and subsequent procedures create recurring revenue opportunities across the patient lifecycle.

• Integrated Platform Economics: Proprietary implants, programming systems, software, and clinical workflows create integrated ecosystems that reinforce customer retention and switching costs.

Next-Generation Implantables

• Hybrid Commercial Models: Emerging manufacturers are exploring licensing, leasing, and flexible financing arrangements alongside traditional hardware sales.

• Software Monetization: Remote programming, therapy optimization, and analytics platforms are creating opportunities for subscription-based and usage-linked software revenue.

• Longitudinal Data Value: Sensing-enabled devices generate physiological data that can support ongoing therapy optimization and potentially enable additional digital services.

Non-Invasive Technologies

• Capital Equipment Sales: Clinic-based platforms such as TMS systems generate revenue through equipment sales to hospitals and treatment centers.

• Recurring Revenue Models: Leasing, per-treatment fees, and software licensing are increasing revenue visibility while lowering upfront investment requirements for providers.

• Commercial Model Innovation: BrainsWay structures approximately 70% of new customer agreements as multi-year recurring contracts, typically spanning four to five years.

Neuromodulation M&A and Private Capital Activity

Strategic M&A Activity

Strategic acquirers are expanding their neuromodulation portfolios through acquisitions of differentiated technologies, particularly in peripheral nerve stimulation and minimally invasive therapeutic platforms.

• Medtronic / SPR Therapeutics: Expands Medtronic’s presence in minimally invasive peripheral nerve stimulation for pain management.

• Boston Scientific / Nalu Medical: Strengthens Boston Scientific’s chronic pain portfolio through miniaturized implantable neurostimulation technology.

• Boston Scientific / Valencia Technologies: Expands Boston Scientific’s pelvic health capabilities through implantable tibial nerve stimulation technology.

• Ottobock / Fesia Technology: Adds functional electrical stimulation capabilities focused on neurological rehabilitation and mobility.

Select Private Raises

These selected transactions illustrate investor interest across implantable, wearable, and non-invasive technologies, with capital supporting clinical development, commercialization, and expansion into new therapeutic indications.

Neuromodulation Industry Outlook

• Adaptive Stimulation Reshaping Therapy Delivery: Closed-loop DBS and SCS systems are shifting treatment from fixed stimulation toward real-time, patient-responsive therapy, improving precision and supporting product differentiation.

• PNS Attracting Strategic Investment: Minimally invasive peripheral nerve stimulation is gaining momentum as manufacturers seek differentiated, non-opioid pain-management technologies with expanding clinical applications.

• Software Becoming a Competitive Differentiator: AI-driven programming, remote monitoring, and automated therapy optimization are extending device functionality beyond hardware and creating opportunities for recurring software revenue.

• Non-Invasive Platforms Expanding Treatment Access: TMS, transcutaneous stimulation, and wearable technologies are reducing procedural barriers and supporting the migration of selected treatments toward outpatient and at-home settings.

• Recurring Revenue Models Gaining Traction: Leasing, per-treatment fees, software subscriptions, and replacement cycles are creating opportunities for manufacturers to generate revenue beyond initial device sales.

• Reimbursement Remains Critical to Commercial Adoption: Established technologies benefit from defined coding and coverage pathways, while emerging platforms must demonstrate clinical efficacy, favorable provider economics, and payer acceptance to achieve scale.

• Strategic Consolidation Expected to Continue: Large MedTech manufacturers are positioned to pursue acquisitions of innovative neuromodulation technologies to strengthen product portfolios, expand therapeutic coverage, and leverage established commercial infrastructure.

Healthcare Desk Perspective

Neuromodulation represents an attractive area of MedTech innovation, with technological advancements and expanding clinical applications creating opportunities across established and emerging platforms.

From an investment perspective, the most compelling opportunities are likely to combine differentiated clinical outcomes, scalable commercialization models, and sustainable recurring revenue streams.

While established manufacturers retain advantages in reimbursement, physician relationships, and commercial infrastructure, emerging companies developing targeted stimulation, adaptive therapies, and non-invasive platforms may become attractive acquisition or partnership candidates.

As neuromodulation evolves toward more intelligent, connected, and accessible treatment systems, strategic M&A and private capital investment are expected to remain important drivers of market development.

See More on the Report Below

Neuromodulation Devices Fall 2026 2026

2.15MB ∙ PDF file

Download

Download

Women’s Health Market Based on Indications

Investor Preferences Across Women’s Health HCIT Segments

• Maternal Health & Postpartum: Integrated EHR and remote monitoring platforms are attracting investment as hospitals and payers seek better care coordination and fewer pregnancy complications. VC favors emerging technologies, while growth equity prioritizes established hospital adoption and payer contracts.

• Fertility & IVF: Specialized EHR, telehealth and Pharma IT platforms benefit from recurring revenue, high switching costs and employer-sponsored fertility benefits. PE favors established platforms with consolidation potential, while VC targets AI-driven embryo analytics and clinical innovation.

• Breast & Gynecological Oncology: High treatment costs increase demand for RCM automation and precision medicine. PE targets profitable billing platforms, while VC and growth equity focus on proprietary genomic data, pharmaceutical customers and recurring analytics revenue.

• Menopause & Midlife: Growing insurance coverage and employer partnerships are creating recurring revenue opportunities for virtual care platforms. VC favors emerging care models, while growth equity seeks proven patient retention and insurance coverage.

• Chronic Gynecological Conditions: Diagnostic delays in PCOS and endometriosis are driving investment in telehealth, AI diagnostics and biomarker research. Early-stage VC focuses on care innovation, while life sciences VC targets proprietary technologies with clinical validation potential.

• Pelvic Health & Incontinence: Home-based rehabilitation and connected monitoring are creating opportunities for digital therapeutics. VC and impact investors favor platforms that improve access, treatment adherence and measurable clinical outcomes.

  Select Private Equity and Venture Capital Portfolio

M&A Transactions in Past 12 Month

See More on the Report Below

Hcit Women's Health Deep Dive Oct 2026

2.21MB ∙ PDF file

Download

Download

Biotech Market Performance

Macro Trends

Improving financing conditions and M&A activity are easing capital constraints across biotech. However, clinical validation, regulatory predictability and commercial differentiation remain central to investment decisions.

• Macroeconomic Headwinds: Higher interest rates could pressure biotech valuations despite improving financing conditions.

• FDA & Regulatory Stability: Leadership changes are helping reduce uncertainty and improve regulatory predictability.

• Clinical Development: Validated biomarkers, meaningful clinical outcomes and trial endpoints are becoming increasingly important.

• Pharma M&A: Buyers are favoring lower-valued early-stage assets or clinically de-risked, near-commercial programs.

• Competitive Differentiation: Efficacy, tolerability and dosing convenience are increasingly driving competitive positioning.

• China’s Strategic Role: China is becoming more important in global biotech R&D, licensing and partnerships despite policy uncertainty.

Venture Transactions by Therapeutic Area

Early-Stage Financing Trends in 2026 - Biotech

• Financing Recovery: Healthcare venture investment reached $31B across 1,101 deals in 1H 2026, with Q2 recording $16.2B across 569 deals.

• Investment Strategy: Investors continue favoring a barbell approach, backing early-stage biotech companies alongside large, later-stage financing rounds.

• Round Dynamics: Improving M&A activity and investor confidence are supporting a gradual return to traditional financing structures, although capital remains concentrated in larger deals.

• Biopharma Dominance: Biopharma accounted for 50% of healthcare venture funding in 1H 2026, up from 45% in 2025, maintaining its position as the leading investment segment.

  

Follow On Data

See the Report Below

Biotech Monthly Insights October 2026

1.74MB ∙ PDF file

Download

Download

Recent credit-market developments at CoreWeave highlight rising financing risks across the AI infrastructure sector. Higher borrowing costs, customer concentration, and substantial capital requirements are increasing pressure on infrastructure operators.

Hyperscalers, specialized cloud providers, and foundation-model developers continue to invest hundreds of billions of dollars in GPUs, data centers, and long-term computing agreements. These investments require substantial upfront capital, with expenditures outpacing near-term revenue and operating cash flow.

The central question is whether infrastructure providers can generate sufficient cash flow to support their debt obligations and future investment requirements.

At a Glance

• CoreWeave Leverage: $35.1B in debt and $16.3B in operating lease liabilities as of 2Q26, with net leverage of 6.6x trailing adjusted EBITDA.

• Capital Requirements: CoreWeave guided to $35–39B in 2026 CapEx, with an estimated $102B funding gap during 2027–2030.

• Contracted Revenue: CoreWeave reported ~$104B in backlog, with 40% expected to convert into revenue over the following 24 months.

• Credit-Market Repricing: CoreWeave’s 2032 unsecured notes traded at yields approaching 15% in October 2026, compared with its 9.5% weighted-average borrowing cost in 2Q26.

• Sector Financing Costs: Non-investment-grade-backed project financing yields widened ~150 bps over two months, compared with 60 bps for investment-grade-backed financing.

• Foundation-Model Commitments: Research estimates Anthropic’s future infrastructure commitments at ~$518B and projects ~$278B in cumulative negative FCF for OpenAI during 2026–2030.

CoreWeave’s Credit Problem: Leverage and Financing Requirements

Capital Structure and Financial Leverage

CoreWeave primarily finances its GPU infrastructure through debt backed by computing equipment and long-term customer contracts, supplemented by corporate borrowing and operating leases.

As of 2Q26, CoreWeave reported net leverage of 6.6x trailing adjusted EBITDA, increasing to 10.3x after including operating leases.

Its financing obligations include:

• Delayed-Draw Term Loans ($13.6B): Senior secured borrowing backed by GPUs and customer contracts.

• Senior Unsecured Notes ($10.0B): Parent-level debt without designated collateral.

• Convertible Senior Notes ($6.5B): Corporate debt with equity conversion features.

• Equipment and Software Facilities ($4.8B): Primarily equipment-backed borrowing.

• Operating Lease Liabilities ($16.3B): Long-term data center obligations, separate from financial debt.

Balances as of June 30, 2026.

The capital structure creates two distinct credit exposures:

• Project-Level Secured Debt: Lenders hold claims against designated infrastructure assets and contractual cash flows. CoreWeave reported $20.8B in project-financing collateral assets, including $18.2B in long-term infrastructure assets and $2.6B in current assets.

• Parent-Level Unsecured Debt: Senior unsecured and convertible notes total approximately $16.5B, or 47% of financial debt. These obligations lack direct security over project assets and carry greater exposure to corporate refinancing conditions.

Infrastructure Financing Requirements

During the All-In podcast discussion, Chamath estimated that CoreWeave carried approximately $35B in existing debt and required another $35B to fund infrastructure commitments.

• 2026 CapEx: $35–39B in guidance, including $14.1B spent in 1H26 and $20.9–24.9B implied for 2H26.

• 2027–2030 CapEx: ~$260B in projected cumulative infrastructure investment.

• Operating Cash Flow: ~$158B in projected cumulative cash generation.

• Funding Gap: ~$102B in estimated additional capital requirements, potentially funded through debt, convertibles, customer prepayments, or equity.

Credit-Market Repricing

CoreWeave’s unsecured debt has experienced substantial market repricing.

• Unsecured Bond Yields: Its 2032 senior unsecured notes reportedly traded below 80 cents on the dollar in October 2026, implying yields approaching 15%.

• Credit Default Swaps: Five-year CDS spreads reportedly exceeded 1,000 bps, compared with 855 bps in earlier research.

• Borrowing Costs: CoreWeave’s weighted-average cost of debt was 9.5% in 2Q26, down from 14.9% in 2023.

• Interest Sensitivity: Financing an additional $35B at 15% instead of 8.5% would increase annual interest expense by approximately $2.3B, assuming fully drawn, interest-only borrowing.

Note: The 15% yield reflects market pricing for a specific unsecured instrument

CoreWeave also held $11.6B in floating-rate debt as of 2Q26. Every 100-bps rate increase would add approximately $30M in quarterly interest expense.

Estimated debt service coverage ratios (DSCRs) decline from 1.57x at an 8% borrowing cost to 1.25x at 10% and 0.84x at 15%. Certain newer facilities require DSCR above 1.35x, indicating potential covenant pressure if applicable financing costs rise.

CoreWeave’s ~$104B contracted backlog provides revenue visibility, with 40% expected to convert over the next 24 months. Its three largest customers accounted for 72% of 2Q26 revenue.

AI Infrastructure Financing: The Economics of Long-Term Customer Contracts

Project Financing and Customer Contracts

Infrastructure providers commonly use special-purpose vehicles (SPVs) to finance GPU clusters through loans secured by computing equipment and contracted customer cash flows.

CoreWeave founder indicated that a typical five-year computing agreement could recover the initial infrastructure investment in ~2.5 years.

Long-term contracts give lenders predictable revenue and secure computing capacity for customers. Financing terms depend on customer creditworthiness, contractual protections, and expected cash generation.

Fixed-Price Contracts vs. Spot-Market Pricing

Long-term contracts support higher borrowing capacity. Short-term computing agreements offer potential revenue upside but generally require more equity.

• Long-Term Contracts: Five-year agreements can support approximately 80% loan-to-cost financing, with an illustrative net present value (NPV) of $11.3M per MW.

• Spot-Market Pricing: Short-term capacity has reportedly commanded up to $40M per MW annually. A separate rolling two-year contracting model generates an estimated eight-year NPV of $27.8M per MW.

• Financing Trade-Off: Uncontracted capacity may support only 50% loan-to-cost financing, increasing equity requirements and exposure to future utilization and pricing.

During the All-In discussion, Chamath highlighted the revenue opportunity from spot pricing. Ben Horowitz emphasized that lenders often require long-term contracts before financing infrastructure development.

Customer Prepayments and Alternative Financing

Recent neocloud transactions reportedly covered 45–55% of GPU CapEx through upfront customer payments. Asset managers such as Brookfield and KKR provide project financing, while NVIDIA supports certain operators through minimum revenue arrangements in exchange for a share of future rental revenue.

Infrastructure Returns: Construction, Customer Economics, and Future Compute Demand

Strong computing demand supports infrastructure investment, but project returns depend on when capacity becomes operational, how long GPUs remain economically useful, and whether customers can sustain their spending.

Construction and Power Constraints

Infrastructure operators must secure electricity, grid connections, cooling systems, and specialized equipment before generating revenue.

• Grid Delays: U.S. grid interconnection typically takes 1–3 years, extending up to seven years in certain high-demand markets.

• Equipment Shortages: Power transformer lead times reportedly exceed three years, with gas turbine supply constraints extending toward 2030.

• Project Execution: Oracle’s Project Jupiter reportedly experienced a gas pipeline delay that pushed scheduled energization to February 2027 and raised the possibility of rent deferrals.

Construction delays postpone revenue while financing and development costs continue.

Operating Models and GPU Useful Life

AI infrastructure operators use different business models with varying investment requirements and payback periods.

• Vertically Integrated AI Cloud: Approximately two-year payback, with operators owning computing equipment and data center infrastructure.

• GPU-as-a-Service: Approximately 2.5–3-year payback, with returns driven by GPU rental pricing and utilization.

• Traditional Colocation: Payback exceeding five years, supported by longer-duration infrastructure leases.

These research-estimated payback periods reflect different commercial models and project costs.

GPU useful life also influences project economics. CoreWeave depreciates its computing equipment over six years, while equipment-backed lenders typically finance 50–70% of collateral value. Continued demand for older GPUs can extend revenue generation, while faster obsolescence reduces potential asset recoveries.

Foundation-Model Financing: Can Customers Sustain Their Commitments?

Infrastructure operators rely on long-term payments from foundation-model developers, making customer financial capacity an important consideration for lenders.

• OpenAI: Research estimates an annualized net revenue run rate of ~$50B in September 2026 and projects ~$278B in cumulative negative FCF during 2026–2030.

• Anthropic: Research estimates ~$518B in future cloud and infrastructure commitments, with approximately 80% described as noncancellable or payable regardless of utilization.

Anthropic could require $200–250B in equity financing to support its infrastructure obligations.

Hyperscalers and semiconductor suppliers, including Amazon, Microsoft, and Broadcom, also provide financing to foundation-model developers that purchase their computing services and hardware. These arrangements support infrastructure demand while linking supplier revenue to customer funding capacity.

Customer Credit Quality and Infrastructure Borrowing Costs

• Credit Spread Widening: UBS Research reported that non-investment-grade-backed project financing yields widened approximately 150 bps over two months, compared with 60 bps for investment-grade-backed projects.

• Cash Flow Impact: Jefferies Research estimated that a 250-bps borrowing-cost advantage could generate approximately $60,000 in additional cash flow per MW, even for a project with lower operating income.

Customer credit quality can affect project cash flow independently of infrastructure operating performance.

Compute Efficiency, Utilization, and Future Pricing

The growth of inference workloads could support more consistent infrastructure utilization as foundation models enter commercial deployment.

Research estimates inference-focused cloud spending at ~$20.6B in 2026, potentially exceeding training-related spending.

Training requires large computing clusters for model development. Inference generates recurring demand through application usage, connecting infrastructure consumption more directly to end-market adoption.

Model efficiency introduces another variable.

• Efficiency Gains: Jefferies Research estimates smaller language models can reduce computing and energy costs by 50–85% for applicable workloads.

• Demand Expansion: Lower computing costs can stimulate application development and increase workload volume, potentially offsetting efficiency gains.

The financial outcome depends on whether workload growth offsets lower computing consumption per task and declining infrastructure rental prices.

Long-term contracts can protect agreed revenue during their contractual terms. Future contract renewals will reflect prevailing computing demand, utilization, and market pricing.

AI infrastructure demand remains strong, but future returns depend on construction execution, customer funding capacity, GPU useful life, and the economics of computing consumption.

Subscribe now

Sources: Wall Street equity research; All-In Podcast, Episode #293, “CoreWeave Crash, AI Trade Cracks, Anthropic IPO Red Flags, Bill Gates Doomer,” October 17, 2026, featuring Chamath Palihapitiya, Ben Horowitz, Jason Calacanis, and David Sacks.

Note: Financial projections, modeled scenarios, and private-company estimates reflect cited research and commentary rather than independently verified company disclosures.

At a Glance

• $500M+ in Medicare Remote Physiologic Monitoring (RPM) payments: Medicare payments exceeded $500 million in 2024.

• 43% of RPM beneficiaries: A federal review identified gaps in remote monitoring service delivery and billing oversight.

• 2027 Medicare proposals: CMS is reviewing reimbursement valuations, clinical staffing requirements, and monitoring billing structures.

  Subscribe now

1. Medicare Reimbursement Has Expanded Digital Health Commercialization

AI is reducing software development costs and improving operating efficiency, while Medicare reimbursement provides additional commercialization opportunities beyond subscriptions and out-of-pocket payments.

Three care management and monitoring categories support recurring reimbursement for eligible clinical services:

• Chronic Care Management (CCM): Monthly reimbursement for coordinating care for patients with multiple qualifying chronic conditions.

• Remote Physiologic Monitoring (RPM): Reimbursement for physiologic monitoring, including blood pressure and weight, alongside qualifying device and clinical management services.

• Remote Therapeutic Monitoring (RTM): Reimbursement for monitoring treatment adherence, therapeutic response, and related clinical management activities.

These pathways enable providers to generate recurring revenue from ongoing patient care rather than relying exclusively on episodic encounters.

Medicare RPM payments exceeded $500 million in 2024. Historical CMS data cited in the research report also indicates that only 4% of approximately 22.6 million clinically eligible Medicare fee-for-service beneficiaries received CCM services, suggesting opportunities for increased utilization.

2. CMS Scrutiny is Reshaping Reimbursement and Clinical Operating Requirements

Federal regulators are increasing oversight of Medicare care management and monitoring services, focusing on patient eligibility, service delivery, and billing accuracy.

A 2024 Health and Human Services Office of Inspector General (HHS-OIG) review identified service delivery gaps affecting approximately 43% of RPM beneficiaries. In March 2026, HHS-OIG added CCM payments to its audit work plan, focusing on beneficiary eligibility.

Separately, CMS proposed changes under its Calendar Year (CY) 2027 Medicare Physician Fee Schedule (PFS).

Key Regulatory Proposals and Enforcement Developments

• Clinical Staffing: CMS proposes limiting reimbursement for certain RPM and RTM activities to clinical staff directly employed by the billing practice. Outsourced monitoring providers could face operating model restructuring, while software-only vendors generally have less direct exposure.

• Patient Initiation: Proposed requirements include a separately reportable initiating visit for RPM and RTM and restrictions on RTM services for new patients, potentially increasing onboarding costs.

• Reimbursement Valuations: CMS proposes revising practice expense valuations for remote monitoring, potentially affecting reimbursement per patient and gross margins.

• Billing Code Consolidation: CMS is considering replacing 17 RPM and RTM codes with four bundled HCPCS G-codes. GRPM1/GRTM1 would cover initial setup, while GRPM2/GRTM2 would combine monthly device supply, transmission, and clinical management. The contemplated monthly codes require at least 20 minutes of treatment management and real-time patient interaction, potentially limiting separate device supply reimbursement.

• Enforcement and Payment Recovery: Regulatory scrutiny creates exposure to claim reviews, payment suspensions, and recoveries. In June 2026, Circle Medical and related parties agreed to a $3.3 million settlement involving allegations of improper provider billing, without a determination of liability. Separately, CMS has proposed expanded retroactive Medicare enrollment revocation and payment recovery authority.

Regulatory Status: The staffing, initiation, valuation, and enrollment enforcement changes remain proposals. Code consolidation is under consideration through a request for comments. None of these proposed changes are finalized as of October 16, 2026.

3. Financial and Operating Implications for Digital Health

• Revenue Quality and Concentration: Companies reliant on a narrow set of CPT codes face greater regulatory exposure, making reimbursement realization, denial rates, and revenue concentration important underwriting metrics.

• Clinical Operating Costs and Gross Margins: AI reduces administrative costs but does not eliminate clinical staffing and supervision requirements. Proposed restrictions on outsourced personnel could increase fixed labor costs, compress gross margins, and constrain operating leverage.

• Customer Acquisition and Patient Economics: Reimbursement eligibility and clinical onboarding affect customer acquisition cost (CAC), lifetime value (LTV), and payback periods. Enrollment growth may not translate into proportional revenue growth, making collections per qualifying patient, retention, and contribution margins important measures of unit economics.

• Working Capital and Cash Flow: Payment delays, claim reviews, suspensions, and potential clawbacks can disrupt liquidity, particularly for Medicare-dependent businesses.

AI Efficiency Versus Clinical Delivery Requirements

Julie Yoo, General Partner at a16z, highlighted the continuing commercialization requirements in a StartUp Health podcast, noting that faster product development does not eliminate the need to:

“build a sales force, distribute to the market, to integrate”

Yoo specifically cited Epic integration as a persistent commercialization challenge despite improvements in software development efficiency.

For reimbursement-dependent businesses, technology scalability does not necessarily translate into clinical service scalability. Operating leverage remains tied to clinical delivery costs, provider relationships, and reimbursement requirements.

4. The Changing Investment Framework for Digital Health

Funding remained concentrated in larger rounds, with financings of $100 million or more accounting for 45% of total funding in 1H 2026. According to Rock Health, U.S. digital health startups raised $7.4 billion across 244 transactions during the period, compared with $6.4 billion across 245 transactions in 1H 2025.

Point Solutions Versus Integrated Platforms:Companies dependent on a limited number of reimbursement codes face greater revenue concentration risk. Integrated platforms may diversify revenue across clinical services, software subscriptions, and payer contracts, although additional reimbursement categories can introduce greater operating and regulatory complexity.

Capital Markets Outlook

AI is expanding digital health commercialization opportunities, while increasing Medicare scrutiny introduces reimbursement uncertainty. For investors, revenue quality, regulatory exposure, operating margins, and cash flow sustainability remain central to financing, valuation, and strategic transactions.

Sources

1. CMS — CY 2027 Medicare Physician Fee Schedule Proposed Rule

2. HHS-OIG — Audit of Medicare Payments for Chronic Care Management Services

3. HHS-OIG — Billing for Remote Patient Monitoring in Medicare

4. HHS-OIG — Additional Oversight of Remote Patient Monitoring in Medicare Is Needed

5. CMS — CY 2027 Home Health Prospective Payment System Proposed Rule

6. U.S. Department of Justice — Circle Medical Settlement, June 2026

7. Rock Health — H1 2026 Funding and Market Overview

Beyond historical financial performance, PE underwriting incorporates forward-looking assumptions on revenue growth, margin expansion, capital requirements, and potential exit valuation.

Key Areas of Investor Evaluation

• Revenue Quality: ARR, recurring revenue mix, contract terms, and customer concentration.

• Retention: Gross and net revenue retention, cohort performance, and churn drivers.

• Pricing: Historical increases, discounting, willingness to pay, and expansion opportunities.

• Profitability: EBITDA margins, free cash flow, and operating leverage.

• Sales Efficiency: Customer acquisition cost, payback periods, and lifetime value.

• Technology: Technical debt, development productivity, infrastructure costs, and cybersecurity.

• Management: Organizational efficiency, leadership capabilities, and execution capacity.

• M&A Opportunities: Acquisition pipeline, integration requirements, and achievable synergies.

1. The PE Investment Thesis: Assessing Acquisition Opportunities

• Recurring Revenue and Cash Flow Visibility: Buyers assess ARR, recurring revenue mix, contract duration, renewal terms, and customer concentration to evaluate revenue predictability and debt-financing capacity.

• Customer Retention and Revenue Expansion: GRR and NRR measure revenue stability and expansion potential. Strong retention reduces reliance on new customer acquisition, while upselling and cross-selling support growth.

• Growth Potential: Buyers evaluate customer acquisition, geographic expansion, cross-selling, and product extensions against the investment required to achieve growth.

• Profitability and Cash Conversion: EBITDA margins, free cash flow, capitalized development costs, and working capital requirements indicate the capacity to service debt, reinvest, and fund acquisitions.

• Competitive Positioning and Switching Costs: Product differentiation, workflow integration, customer dependence, and competitive alternatives influence revenue durability and customer switching risk.

• Platform and Add-On Acquisition Potential: Buyers assess the company’s suitability as a standalone platform or add-on acquisition, including consolidation opportunities, distribution expansion, and operating synergies.

2. Buyer Due Diligence: Underwriting Financial and Operating Performance

• Revenue Quality and Cohort Performance: Buyers assess ARR reconciliation, recurring revenue mix, customer concentration, cancellations, and cohort performance to distinguish retention-driven growth from growth dependent on customer replacement.

• Pricing and Monetization: Investors evaluate subscription tiers, historical pricing, discounts, renewal increases, and willingness to pay to identify revenue expansion opportunities without materially increasing churn.

• Customer Acquisition Economics: CAC, LTV, payback periods, sales productivity, and acquisition channels help buyers assess the scalability and efficiency of customer growth.

• Operating Expense Structure: Buyers evaluate engineering, product development, sales, marketing, and administrative costs to identify operating leverage and sustainable efficiencies without compromising product quality or customer service.

• Technology and Product Infrastructure: Technical debt, cybersecurity, cloud costs, infrastructure, development productivity, and third-party dependencies inform future investment needs and integration risks.

• Management and Organizational Capabilities: Buyers assess leadership depth, succession planning, founder dependence, and management’s ability to execute growth and operational improvements.

• Financial Quality of Earnings: Revenue recognition, deferred revenue, EBITDA adjustments, capitalized R&D, and cash conversion help establish sustainable earnings and support the company’s valuation basis.

Due diligence findings can directly influence purchase price, financing terms, required seller protections, and transaction certainty.

3. Post-Acquisition Value Creation: How PE Buyers Seek to Improve Returns

Pricing and Revenue Optimization

• Subscription Pricing: Buyers assess pricing relative to customer value and competition to identify revenue growth opportunities while managing potential churn.

• Product Packaging and Monetization: Subscription restructuring, usage-based pricing, and monetization of free features can increase revenue per customer, depending on willingness to pay.

• Customer Expansion: Upselling, cross-selling, and product extensions can increase revenue from existing customers and reduce reliance on new customer acquisition.

Operating Example — Evernote’s Pricing Strategy

Following Bending Spoons’ acquisition, Evernote increased subscription prices in 2023. In an interview with The Twenty Minute VC (20VC), Bending Spoons product leader Federico Simeonato estimated the increase at approximately 50–60%.

The company anticipated some customer attrition but considered the pricing change supportable based on the utility provided to its subscriber base.

As Simeonato explained:

“It all boils down to how useful the product is for you.”

The example illustrates how a software acquirer can assess pricing opportunities against customer retention and perceived product value. The interview does not establish the financial returns generated by the pricing initiative.

Bending Spoons operates shared corporate and technology infrastructure across its software portfolio.

Simeonato described the organizational structure as:

“A horizontal platform to which we plug individual products.”

The company centralizes certain support functions while retaining dedicated teams responsible for product development, monetization, and growth.

During the interview, Simeonato stated that Evernote’s business unit had declined from several hundred employees to fewer than 100.

For PE buyers, the relevant consideration is whether operating efficiencies are achievable without undermining product performance, revenue retention, or future growth.

Customer Retention and Product Investment

Operating Example — Evernote’s Retention Strategy

During the 20VC interview, Simeonato identified subscriber retention as Evernote’s most important product success metric.

This approach illustrates the relationship between product utility and recurring revenue durability. Improving retention can create economic value even when the immediate revenue impact of a specific feature is limited.

Buy-and-Build Expansion

Buy-and-build strategies can accelerate scale through complementary acquisitions, distribution expansion, and operating synergies. However, the economic benefit depends on acquisition pricing, integration costs, and the sustainable earnings contribution of each acquired company.

4. Selling to Private Equity: Considerations for CEOs, CFOs, and Founders

A company preparing for a PE transaction should evaluate its business through the same financial and operating framework used by prospective investors.

Beyond preparing diligence materials, sellers should consider how the buyer’s investment thesis influences the economics and structure of a proposed transaction.

Understanding How Buyer Underwriting Affects Sale Outcomes

• Valuation and Future Upside: Assessment of revenue growth, margin expansion, and allocation of future value between buyer and seller.

• Buyer Selection: Evaluation of financial sponsors, platform investors, and strategic acquirers based on investment strategy and synergy potential.

• Quality of Financial Information: Reliable ARR, retention, profitability, and cash flow reporting to support valuation and reduce diligence uncertainty.

• Management Continuity and Incentives: Post-closing responsibilities, management autonomy, incentive plans, and performance requirements.

• Transaction Structure: Cash consideration, rollover equity, earnouts, deferred payments, and liquidity at closing.

• Rollover Equity and Future Participation: Exposure to future equity returns, leverage, dilution, governance restrictions, and exit risk.

• Execution and Integration Risk: Buyer track record, integration capabilities, financing certainty, and planned operational changes.

• Pre-Sale Preparation: Financial reporting, customer concentration, pricing practices, technology risks, and management dependencies.

5. Conclusion

Ultimately, the value realized in a sale depends not only on the buyer’s expected post-acquisition improvements, but also on how that potential upside is reflected in the purchase price and transaction structure.

Subscribe now

_Source

1. _{McKinsey & Company. Five Considerations for Software Private Equity in 2024. March 1, 2024. Analysis of software investment opportunities, go-to-market effectiveness, pricing, R&D productivity, and M&A value creation.
   https://www.mckinsey.com/industries/private-capital/our-insights/five-considerations-for-software-private-equity-in-2024}

2. _{McKinsey & Company. Pricing: The Next Frontier of Value Creation in Private Equity. October 23, 2019. Research on pricing improvement opportunities in acquisition diligence and portfolio operations.
   https://www.mckinsey.com/capabilities/growth-marketing-and-sales/our-insights/pricing-the-next-frontier-of-value-creation-in-private-equity}

3. _{Bain & Company. Global Private Equity Report 2025. Research on software acquisition returns, margin improvement, and the importance of integrated commercial, technical, and operational due diligence.
   https://www.bain.com/insights/topics/global-private-equity-report/}

4. _{The Twenty Minute VC (20VC). Harry Stebbings, interview with Federico Simionato, Bending Spoons product leader}

_{Research note: The private equity investment framework reflects general industry practices and may vary by investment strategy, software subsector, company size, and transaction structure. Bending Spoons is presented as a software acquisition and operating example, not as a representative}

Lifecore Acquired by Webster Equity Partners

Strategic Rationale

• Accelerate Commercialization: Leverage Webster’s capital and healthcare expertise to advance Lifecore’s late-stage pipeline and support new commercial launches.

• Improve Capacity Utilization: Increase production volumes across existing ash consideration at a premium, alongside potential contingent payments tied to future performance.

Management Commentary

• Paul Josephs, CEO: Highlighted 13 late-stage programs with commercialization potential by 2028, supporting future revenue growth and customer diversification.

• Paul Josephs, CEO: Emphasized the extension of Alcon’s manufacturing agreement through 2034, strengthening long-term revenue visibility.

• Paul Josephs, CEO: Outlined targets of 12% revenue CAGR and adjusted EBITDA margins exceeding 25% by 2029, supported by commercial launches and operational improvements.

• Matthew Beer, Webster Partner: Highlighted the opportunity to combine Webster’s healthcare expertise with Lifecore’s CDMO capabilities to improve operational efficiency and achieve sustainable profitability.

Lifecore Biomedical Overview

Business Model

• Lifecore Biomedical is a specialized CDMO focused on complex sterile injectables and pharmaceutical-grade hyaluronic acid (HA).

• Provides end-to-end development and manufacturing services, from formulation and analytical testing to commercial-scale production.

• Generates revenue through development fees, long-term manufacturing contracts, and HA product sales, supported by recurring commercial production.

Product Overview

• Hyaluronic Acid (HA): Manufactures pharmaceutical-grade HA for ophthalmic, orthopedic, and aesthetic applications using proprietary fermentation technology.

• Sterile Injectable Products: Produces complex HA-based and non-HA injectable pharmaceuticals and medical devices.

• Aseptic Fill-Finish: Provides sterile filling and packaging for prefilled syringes, vials, and cartridges.

• Development Services: Offers formulation development, analytical testing, process validation, technology transfer, and clinical trial manufacturing.

Geographic Footprint

Financial Overview

Major Customers

Evolution of Lifecore Biomedical

Synergy with Webster Equity Partner Portfolio Companies

Pharma CDMO Industry Outlook

• Growth in Pharmaceutical Outsourcing: Increasing drug complexity and R&D spending continue to drive outsourcing demand, with the global CDMO market projected to grow at approximately 17% annually through 2032, depending on market definition.

• Rising Demand for Sterile Injectables: Growth in biologics, GLP-1 therapies, and complex formulations is supporting demand for aseptic fill-finish services, with the market projected to reach $21B by 2030.

• Private Equity and M&A Consolidation: The fragmented CDMO market continues to attract investors seeking specialized manufacturing capabilities and opportunities to build broader pharmaceutical services platforms.

• Shift Toward Domestic Manufacturing: Pharmaceutical companies are increasingly prioritizing U.S. and European manufacturing facilities to reduce geopolitical and supply chain risks.

• Capacity Utilization and Margin Expansion: CDMOs can improve profitability by increasing production volumes across existing facilities, while integrated platforms offer potential cross-selling opportunities and operational efficiencies.

Our Advisory Services

• Equity Capital Raising

• Debt Capital Raising

• Mergers & Acquisitions

• Strategic Alternatives

Why Healthcare Desk?

Research-Driven Sector Expertise

We actively track healthcare developments, financing activity, M&A transactions, and valuation trends to inform financial and strategic decisions.

Institutional Investor Relationships

Our relationships with institutional investors and capital providers support targeted investor engagement and capital raising.

Technology-Enabled Execution

We leverage AI-powered research, automation, and modern tools to streamline workflows, accelerate execution, and deliver cost-efficient advisory services.

Middle-Market & Growth-Stage Focus

We tailor our advisory approach to the financing requirements, growth stages, and strategic objectives of emerging and middle-market healthcare companies.

Therapeutics

• Clinical-Stage & Commercial-Stage Biopharma

• Specialty Pharmaceuticals & Biologics

• Cell & Gene Therapies

MedTech & Diagnostics

• Medical Devices, Surgical Technologies & Robotics

• Molecular Diagnostics & Point-of-Care Testing

• Diagnostic Imaging & Digital Diagnostics

Life Sciences Tools

• Genomics, Proteomics & Molecular Analysis

• Laboratory Instruments & Automation

• Research Reagents & Consumables

Manufacturing

• Contract Development & Manufacturing (CDMO)

• Contract Research Organizations (CRO)

• Medical Device & Pharmaceutical Manufacturing

Healthcare Services Coverage

Healthcare Technology

• Digital Health, Virtual Care & Remote Patient Monitoring

• Electronic Health Records (EHR), Revenue Cycle Management (RCM) & Healthcare IT

• AI-Enabled Clinical & Administrative Technologies

Healthcare Services

• Physician Practices & Specialty Care

• Outpatient Care, Ambulatory Surgery Centers & Alternate-Site Services

• Healthcare Business Services & Outsourced Solutions

• Managed Care

• Health Systems

• Industry Expertise

• Institutional Investor Perspectives

• Market Research & Insights

Our approach integrates AI/technology-enabled workflows to accelerate deal execution.

The Healthcare Desk 60-Day Process

DAYS 1–15: Research & Preparation

Market positioning, valuation analysis, investor targeting, and transaction materials.

DAYS 16–30: AI-Enabled Outreach

Target screening, investor prioritization, and structured institutional outreach.

DAYS 31–45: Investor Engagement

Investor discussions, management introductions, feedback, and initial diligence.

DAYS 46–60: Transaction Progress

Qualified interest, follow-ups, and defined next steps

_{Illustrative process targets, not historical performance claims or guaranteed outcomes.}

How We Help

We support healthcare companies at critical stages of growth, financing, and strategic transformation.

Navigate Capital Markets

Identify financing opportunities through industry research, market trends, and investor sentiment.

Connect with Institutional Capital

Engage institutional investors aligned with companies’ financing needs and growth objectives.

Make Informed Financial Decisions

Evaluate capital structures, valuations, and financing alternatives to guide financial strategy.

Execute Strategic Transactions

Support capital raising, M&A, and corporate transactions from evaluation through execution.

Strategic Rationale:

VitalConnect is a cardiac monitoring company built around VitalPatch, a wearable biosensor used across ambulatory, inpatient and hospital-to-home settings.

iRhythm is a cardiac monitoring company built around the Zio service.

• Expand MCT coverage: VitalPatch adds 30-day monitoring, live look-in and more workflow flexibility, helping iRhythm reach nearly the full mobile cardiac telemetry market.

• Accelerate multi-vitals: VitalConnect gives iRhythm an existing platform for monitoring multiple physiological signals and supports expansion into areas such as sleep apnea and heart failure.

• Enter new care settings: The acquisition expands iRhythm into inpatient monitoring, post-discharge care and hospital-to-home programs.

• Scale VitalConnect: iRhythm can distribute VitalPatch through its larger salesforce, payer relationships and EHR integrations.

• Improve integration and costs: iRhythm plans to move VitalPatch onto ZEUS, consolidate IDTF operations and integrate it into ZioSuite over time.

• Support growth while keeping the core strategy: The deal broadens iRhythm’s portfolio while the company continues developing next-generation Zio MCT and maintains its profitability targets.

Management Commentary of iRhythm Relevant to this Transaction:

• CEO Quentin Blackford said the acquisition moves iRhythm from ambulatory cardiac monitoring toward a broader cardiac monitoring and intelligence platform, adding mobile cardiac telemetry, multi-vitals and inpatient capabilities.

• Blackford noted that Zio AT serves only about half of the mobile cardiac telemetry market, while VitalPatch gives iRhythm access to the full category and an estimated $500 million incremental opportunity.

• Chief Medical and Scientific Officer Mintu Turakhia said no single monitoring model suits every patient or workflow, positioning VitalPatch as a complement to Zio rather than a replacement.

• Management had tracked VitalConnect for several years and waited for the right structural, technical and operating conditions before pursuing the acquisition.

• CFO Dan Wilson had previously acknowledged that iRhythm would need to build or acquire additional capabilities to address parts of the mobile cardiac telemetry market that its existing model could not serve.

• Management sees more value in hospital-to-home monitoring than in basic fee-for-service remote patient monitoring, particularly where multi-vital data can help reduce readmissions.

• iRhythm plans to retain both VitalPatch and next-generation Zio MCT, using a dual-product strategy to address different monitoring durations, patient groups and physician workflows.

• Management expects to place VitalPatch into iRhythm’s national salesforce, use its payer and EHR relationships, and integrate the platform into ZioSuite and ZEUS over time.

• Management committed to keeping combined gross margins above 70% and maintaining its 15% Adjusted EBITDA margin target for 2027 following the acquisition.

• The company framed VitalConnect as a targeted portfolio expansion rather than the start of an aggressive acquisition program, although management is now more open to complementary technology deals.

Vital Connect Overview:

VitalConnect is a digital health company focused on wearable cardiac and patient monitoring through its VitalPatch platform.

• Generates revenue from reimbursed cardiac monitoring episodes, with MCT as the main near-term use case.

• Creates repeat usage through disposable VitalPatch sensors used across longer monitoring periods.

• Operates an IDTF that processes monitoring data and delivers diagnostic reports to physicians.

• Supports ambulatory cardiac monitoring as well as inpatient telemetry and monitored hospital beds.

• Extends the same platform into post-discharge, hospital-to-home and remote patient monitoring.

iRhythm Overview:

iRhythm is a digital health company focused on ambulatory cardiac monitoring through its Zio platform.

• Generates revenue each time a physician orders a cardiac monitoring service for a patient.

• The service includes the wearable device, ECG analysis, technician review and final diagnostic reporting.

• Revenue is largely reimbursed by commercial insurers and Medicare under cardiac monitoring codes.

• Also works directly with hospitals and physician practices under negotiated commercial arrangements.

• Growth is mainly driven by higher test volumes, broader payer coverage and reimbursement levels.

• Strategics are broadening wound care portfolios: Buyers are adding advanced dressings, regenerative technologies, burn care, infection prevention, and home-care distribution to deepen category exposure and expand cross-selling opportunities.

• PE is targeting recurring, fragmented platforms: Sponsor-backed activity remains concentrated in advanced dressings, specialty distribution, chronic wound products, and regenerative technologies, where repeat utilization and fragmented markets support consolidation.

• Reimbursement is reshaping deal underwriting: The 2026 CMS skin-substitute reset reduces the premium-pricing advantage of certain tissue products, increasing the importance of product cost, clinical evidence, regulatory classification, and care-setting exposure.

• Commercial quality is becoming more important: Buyers favor platforms with differentiated outcomes, recurring utilization, broad distribution, and reimbursement resilience over businesses dependent on a narrow product or reimbursement model

Select Wound Care Transactions: Last 18 Months

Advanced Wound Care Market Overview

• The global advanced wound care market is approximately $12B, with the U.S. at roughly $5.5B, supported by aging populations, diabetes, obesity, and rising chronic wound prevalence.

• Providers are moving beyond passive dressings toward advanced dressings, negative pressure wound therapy (NPWT), biologics, and regenerative therapies, while more care shifts to outpatient and home settings.

• Growth is increasingly driven by single-use technologies, digital wound management, advanced biomaterials, and regenerative platforms.

Advanced Wound Care Treatment Pathway

Wound Care Commercialization & Recurring Revenue

• Business Model: Recurring consumables, equipment-linked disposables, per-application therapies, and increasingly software and monitoring products.

• Recurring Revenue Drivers: Repeat dressing changes, NPWT therapy days, proprietary consumables, and embedded clinical protocols create recurring utilization and increase customer lifetime value.

• Commercialization Roadmap: Successful commercialization typically progresses from regulatory clearance and clinical validation to reimbursement, institutional access, pilot adoption, and broader commercial scale.

• Indicators of Scale: Manufacturing capacity, distribution reach, formulary and GPO penetration, and conversion of pilots into standardized protocols are key signals of commercial maturity and operating leverage.

Reimbursement & Regulatory Landscape

• CMS reimbursement reform is resetting skin-substitute economics: Beginning in 2026, CMS moved certain skin substitutes from ASP-based reimbursement to a standardized payment framework, reducing the pricing advantage of premium products and increasing provider sensitivity to acquisition cost.

• The reimbursement shift is accelerating industry consolidation: Manufacturers with heavy exposure to physician-office skin substitutes face greater pressure.

• Regulatory pathways create different capital and evidence requirements: Advanced dressings, synthetic matrices, and many wound care devices can access the market through 510(k) clearance, while certain human tissue products may fall under Section 361 or require the more rigorous Section 351 BLA pathway.

• Clinical evidence is becoming a stronger competitive differentiator: Section 351 products require more extensive clinical development, while broader regulatory scrutiny and EU MDR requirements are raising compliance costs.

  

  Wound Care Market Map

  

  Please see the detailed report below

  

  Wound Care Medical Devices Fall 2026 2026

  2.02MB ∙ PDF file

  Download

  Download

Revenue cycle management (RCM) is becoming a larger part of healthcare operations as providers deal with rising administrative costs, staffing shortages, claim denials and pressure on margins. The U.S. RCM market grew from $158.4 billion in 2020 to $234.5 billion in 2025 and is projected to reach $329.8 billion by 2030, with hospitals accounting for roughly 56% of spending.

Market Scope

• Patient Access: Scheduling, registration, eligibility checks, prior authorization and cost estimation; market expected to grow from $2.8B in 2025 to $4.8B by 2030.

• Clinical & Mid-Cycle: Clinical documentation, charge capture, utilization review and medical coding.

• Claims & Clearinghouse: Claims scrubbing, routing, EDI connectivity and payer-status tracking.

• Denials & Revenue Integrity: Denial prevention, appeals, underpayment recovery and receivables management.

• Patient Payments & Managed RCM: Digital billing, payment plans, collections and outsourced end-to-end RCM; outsourced RCM is projected to reach $69.6B by 2030.

Market Trends

• Shift to Preventive RCM: Providers are addressing eligibility, authorization and denial risks earlier in the workflow.

• AI-Led Automation: AI is automating coding, prior authorization, denials and other administrative workflows.

• Growing Outsourcing: Outsourced RCM penetration is expected to increase from 17% to 21% by 2030.

• Platform Consolidation: Health systems are replacing fragmented point solutions with integrated RCM platforms.

• Outcome-Based Pricing: Vendors are increasingly linking fees to collections, denial reduction and A/R improvement.

Evolution of RCM

RCM Market Segments

RCM Platform Consolidations

RCM Revenue Models & Investor Attractiveness Across the Workflow

M&A Transactions in Past 12 Months

See the Full Report Below:

Hcit Revenue Cycle Management Deep Dive

2.33MB ∙ PDF file

Download

Download

Strategic value is shifting toward de-risked, differentiated and scalable TCE platforms

TCE Market Map

TCE Proposed Mechanism: Immune Reset

Autoimmune therapy is shifting from chronic pathway suppression toward deeper depletion of disease-sustaining immune cells. Conventional immunosuppressants and pathway-specific biologics can control disease activity but typically require chronic administration. TCE represent a different therapeutic approach by recruiting endogenous T cells directly to pathogenic B cells or plasma cells.

Limitations of Conventional Anti-CD20 Depletion

Rituximab and other anti-CD20 antibodies can effectively deplete circulating B cells but may leave residual B-cell populations in lymphoid tissues and other disease-relevant compartments. CD20 also does not cover early B-cell precursors, plasmablasts or plasma cells, allowing these populations to persist, repopulate the B-cell compartment or continue producing pathogenic autoantibodies.

B-Cell Differentiation Creates Different Therapeutic Windows

A simplified disease-relevant B-cell lineage can be viewed as:

Early B-cell precursor → naïve B cell → mature B cell → memory B cell → plasmablast → long-lived plasma cell

CD19, CD20 and BCMA cover different parts of this continuum, making target selection a key determinant of depletion breadth and the residual immune-cell populations that may continue to sustain or regenerate disease.

TCEs redirect endogenous T cells against CD19-, CD20- or BCMA-expressing cells to drive deeper B-cell and/or plasma-cell depletion, with the goal of healthier immune reconstitution and sustained treatment-free benefit.

TCE Target and Molecular Architectures

CD19, CD20 and BCMA cover different stages of B-cell differentiation, while molecular format and engineering strategy determine how TCEs balance depletion depth, tissue penetration, pharmacokinetics and systemic T-cell activation.

Molecular and Safety-Engineering Formats

TCE development is increasingly focused on improving the therapeutic index along with maximizing cytotoxic potency.

• BiTE-like constructs use smaller molecular formats that may improve tissue diffusion but typically require half-life extension to support practical dosing.

• Full-length IgG-like TCEs offer longer systemic exposure, conventional antibody pharmacokinetics, structural stability and established manufacturing, but require tighter control of prolonged systemic T-cell activation.

• Trispecific and multispecific TCEs add a second disease-cell target or an additional activation/costimulatory signal to broaden lineage depletion, reduce antigen escape or strengthen target-cell killing, while increasing molecular complexity and potentially immune activation.

• Masked or conditionally active TCEs restrict CD3 engagement until the molecule reaches the intended target environment, aiming to preserve local cytotoxicity while reducing systemic cytokine release.

• CD3 affinity-detuned TCEs weaken CD3 binding so T-cell activation becomes more dependent on target-cell engagement, with the goal of reducing CRS while maintaining depletion.

• mRNA/LNP-encoded TCEs produce the engager in vivo rather than administering recombinant protein directly. Potential advantages include smoother exposure, lower peak concentrations, flexible redosing and differentiated manufacturing and delivery, although clinical validation remains earlier.

BCMA-containing approaches provide the strongest direct plasma-cell depletion but can increase hypogammaglobulinemia and infection risk as depletion broadens. CRS and ICANS are being addressed through CD3 detuning, masking, subcutaneous administration and slower exposure. BiTE-like formats generally require half-life extension, IgG-like constructs provide longer conventional PK, and encoded approaches may enable more gradual endogenous exposure.

Outpatient feasibility is increasingly linked to lower peak exposure, SC dosing and fewer step-up requirements, while manufacturing complexity generally rises across multispecific, masked and encoded platforms.

Clinical Endpoints in Autoimmune TCE Development

Primary endpoints remain indication-specific, while steroid withdrawal, treatment-free remission and durability after finite therapy provide more differentiated TCE readouts.

• SLE

  • Core efficacy endpoints: SRI-4, BICLA

  • Disease-control / remission measures: LLDAS, DORIS remission

  • Supporting measures: glucocorticoid reduction, complement normalization, anti-dsDNA decline

  • Potential immune-reset readout: sustained remission with reduced or discontinued steroids/background immunosuppression

• Lupus nephritis

  • Key efficacy endpoint: Complete Renal Response (CRR), with definitions varying by trial

  • Core measures: proteinuria (typically UPCR), preserved/stable eGFR and protocol-defined glucocorticoid limits

  • Supporting measures: sustained renal response, proteinuria reduction and kidney-function preservation

  • Potential immune-reset readout: durable renal response with reduced need for chronic immunosuppression

• Rheumatoid arthritis

  • Core efficacy measures: ACR20/50/70, DAS28, CDAI and clinical remission

  • Supporting measures / biomarkers: RF, ACPA/anti-CCP and, for TCEs, depth of B-cell depletion

  • Potential immune-reset readout: sustained remission after finite treatment with persistent disease control after background therapy reduction

• Systemic sclerosis

  • Core efficacy measures: mRSS for skin disease, FVC for pulmonary involvement, CRISS/rCRISS composite measures

  • Supporting measures: ILD progression, qHRCT, DLCO, patient-reported outcomes and autoantibody changes

  • Potential immune-reset readout: durable stabilization or improvement with reduced background immunosuppression

• Myositis

  • Core response endpoint: ACR/EULAR Total Improvement Score (TIS)

  • Component / supporting measures: MMT-8, muscle enzymes including CK, physician/patient global assessments and extramuscular disease activity

  • Potential immune-reset readout: durable major clinical improvement following finite treatment

• ITP

  • Core efficacy measures: platelet response and sustained/durable platelet response

  • Supporting measures: bleeding, rescue-therapy use and reduction/discontinuation of concomitant therapy

  • Potential immune-reset readout: sustained platelet control after finite therapy without ongoing treatment

• AIHA

  • Core efficacy measures: hemoglobin response, normalization of hemoglobin and transfusion independence

  • Supporting measures: normalization of hemolysis markers, response durability and reduction of corticosteroid requirements

  • Potential immune-reset readout: sustained hematologic response without ongoing immunosuppressive therapy

Oncology as the Clinical Precedent

Approved CD19-, CD20- and BCMA-directed TCEs have validated rapid and deep target-cell depletion across heavily pretreated hematologic malignancies. Oncology has also established the key class liabilities—CRS, neurotoxicity, infection, hypogammaglobulinemia, step-up dosing, intensive monitoring and, in some cases, hospitalization. These risks may be acceptable in refractory cancer, but set a materially higher therapeutic-index and treatment-logistics bar for autoimmune disease.

Teclistamab demonstrates the biological power of BCMA-mediated plasma-cell depletion, but was associated in oncology with approximately 90% hypogammaglobulinemia and 41.6% Grade 3/4 infections, alongside high CRS frequency.

Similarly, SC delivery alone is not sufficient to solve class toxicity: epcoritamab still requires step-up dosing and steroid prophylaxis, while CRS remained common in the oncology experience.

Clinical Bar for Emerging and Preclinical TCEs

Emerging programs will increasingly be assessed across five areas: depth, breadth, safety, convenience and durability.

• Depth: Depletion should extend beyond peripheral blood into lymph nodes, bone marrow or disease-relevant tissue where pathogenic immune cells may persist.

• Breadth: Target coverage should match disease biology, whether the relevant compartment is B cells, plasma cells or both.

• Safety: Autoimmune programs need a materially better therapeutic index than oncology TCEs, particularly around CRS, ICANS, infection, hypogammaglobulinemia and cytopenias.

• Convenience: The preferred profile moves toward SC or simple IV dosing, fewer step-up doses, outpatient administration and a short or finite treatment course.

• Durability: The most differentiated durability signal would be sustained treatment-free remission after therapy stops, particularly if maintained after B-cell reconstitution.

The bar is shifting toward deep, disease-relevant depletion with autoimmune-appropriate safety and durable benefit after finite treatment.

_{Source: Public Filings, Wall Street Equity Research}

MedTech M&A Transactions (US, CA, EU) 2022 – Q3 2026

• PE remains selective but active: Sponsors are concentrating capital in scalable, high-quality platforms, while subscale assets continue to face funding pressure.

• M&A can still improve despite high rates: Strong strategic balance sheets, valuation resets, and secular growth in AI, smart implants, and procedure volumes can support deal activity even with financing costs remaining elevated.

MedTech Venture Funding (US, CA, EU) 2023 – Q3 2026

• Capital concentrating at the top: Later-stage, high-quality medtech platforms are attracting outsized checks, while early-stage funding continues to contract.

• Late-stage valuation resilience: Despite lower deal volume, de-risked platforms continue to raise large rounds at relatively strong valuations.

• Early-stage valuation pressure: Seed and Series A financings are smaller, milestone-driven. Capital scarcity is forcing earlier proof points on clinical data, reimbursement, and commercial pathways.

Macro Themes

• M&A remains strategically focused: Buyers continue targeting differentiated assets in cardiovascular, neurostimulation, connected care, and workflow technologies, alongside carve-outs and portfolio repositioning.

• Care is shifting outside the hospital: More procedures are moving to ASCs and office-based settings, increasing demand for smaller, lower-cost, workflow-efficient technologies.

• AI, robotics, and integrated platforms are gaining scale: MedTech companies are combining hardware, imaging, navigation, robotics, software, and data to improve precision, planning, and operating efficiency.

• Recurring revenue is becoming more important: SaaS, consumables, and service models are complementing equipment sales, improving revenue visibility, margins, and customer stickiness.

• Outsourcing and localization are reshaping operations: OEMs are relying more on specialized CDMOs and EMS providers while diversifying supply chains to reduce capital requirements, tariffs, and geopolitical risk.

• China remains a pricing challenge: Volume-based procurement is increasing pricing pressure and forcing global MedTech companies to rethink localization, product positioning, and commercial strategy.

Notable MedTech Transactions: Last 12 months

MedTech Transactions – September 2026

MedTech Earnings Updates

Please see the detailed report below

Medtech Monthly Insights Sept 2026

2.43MB ∙ PDF file

Download

Download

Index Performance: EHR/RCM & Other HCIT (+3.5%) led on resilient recurring revenue, automation and AI adoption, while Pharma Services (-4%) and Benefits/Telehealth (-1%) lagged amid selective investor sentiment

EV / LTM Revenue: EHR/RCM leads at ~7.5x on recurring SaaS revenue and strong margins, followed by Pharma Services at ~4.7x; VBC remains lowest at ~0.45x due to thin margins and medical-cost exposure.

HCIT M&A Highlights

• Selective Consolidation: Deal activity has cooled from Q3’25, but demand remains strong for scalable HCIT platforms with recurring revenue and clear ROI.

• AI & Workflow Focus: Buyers continue targeting AI-enabled RCM, clinical workflows, interoperability and automation.

• Platform Expansion: Strategic and PE buyers are using tuck-ins to broaden capabilities and build more integrated platforms.

• Quality Over Volume: Higher financing costs and regulatory uncertainty are concentrating activity around profitable, differentiated assets.

HCIT Venture Funding Highlights

• More Capital, Fewer Bets: Funding remains resilient despite fewer deals, reflecting larger checks into established market leaders.

• Mega-Rounds Lead: $100M+ rounds accounted for 45% of H1’26 U.S. digital-health funding, highlighting investor preference for scaled businesses.

• AI Is Expected: AI-enabled platforms continue to attract capital, but investors increasingly demand defensible data, distribution and measurable ROI.

• Proof Over Growth: Clinical validation, commercial traction and sustainable unit economics are becoming key requirements for funding.

HCIT Public Market Valuation

Macro Theme

• AI-Native EHR & Clinical Workflows: EHRs are evolving into AI-enabled platforms that embed documentation, decision support and workflow automation directly into care delivery.

• Healthcare Workforce & Workflow Efficiency: Clinician shortages and administrative burden are accelerating demand for automation across documentation, scheduling, credentialing and onboarding.

• Interoperability & Connected Data Ecosystems: FHIR, APIs and cloud infrastructure are enabling more seamless data exchange across EHRs, payers, providers and third-party applications.

• Shift Toward Value-Based Care: Outcome-based reimbursement is increasing demand for technology that improves care quality, lowers costs and demonstrates measurable ROI.

• RCM & Administrative Automation: Rising denials, prior-authorization requirements and administrative costs are driving adoption of AI-enabled billing, claims and payment automation.

• Clinical AI & Imaging Transformation: AI is becoming increasingly embedded within diagnostic and clinical workflows, particularly across imaging and clinical decision support.

• Cybersecurity & Infrastructure Resilience: Growing cyber threats and data breaches are making secure infrastructure, data protection and business continuity critical priorities for providers.

• Regulatory & Reimbursement Modernization: Evolving digital-health frameworks are creating clearer regulatory and reimbursement pathways for software-based healthcare technologies.

• ROI-Driven Technology Spending: HCIT spending is increasingly focused on solutions that deliver measurable productivity gains, cost savings, reimbursement capture and margin improvement.

• Platform Consolidation & Vendor Rationalization: Health systems are favoring integrated platforms over fragmented point solutions, driving further consolidation and strategic M&A across HCIT.

Recent M&A and Venture Transactions

Earnings Update

Please see the detailed report below:

Hcit Monthly Insights September 2026

2.38MB ∙ PDF file

Download

Download

Macro Theme

• Higher rates are re-emerging as a biotech valuation headwind: Renewed inflation concerns and higher Treasury yields are increasing duration risk for development-stage biotech, with valuations vulnerable if financial conditions tighten further.

• FDA / Regulatory — Leadership stabilization is reducing policy uncertainty: Recent CDER and CBER appointments are shifting attention back toward review consistency, scientific standards, and a more predictable regulatory environment.

• Clinical Development — Biomarker validation is becoming a larger underwriting risk: Recent failures highlight that biomarker modulation alone is insufficient, increasing the burden of proof and potentially raising development costs where large outcomes studies are required.

• Clinical Trials — Endpoint design is becoming as important as target biology: Investors are placing greater weight on validated biomarkers, assay reproducibility, and clinically meaningful endpoints before assigning value to early efficacy signals.

• M&A — Pharma underwriting may move toward a barbell strategy: Buyers may increasingly favor either earlier-stage assets acquired at lower valuations or later-stage programs with substantially de-risked clinical profiles, while avoiding expensive assets with unresolved Phase III risk.

• M&A — De-risked revenue may command a higher strategic premium: Phase III-validated, near-commercial, and revenue-generating assets could attract stronger demand, widening the valuation gap versus programs with unresolved translational or endpoint risk.

• Competitive Markets — Product differentiation is becoming more important: As standards of care improve, clinical value is increasingly defined by relative efficacy, tolerability, dosing convenience, and treatment burden rather than efficacy versus placebo alone.

• China — Strategic relevance continues to rise despite policy uncertainty: China is becoming a more structural part of global biotech R&D, licensing, and partnering, rather than simply a source of lower-cost assets.

Recent Venture Transactions

• Healthcare venture activity is accelerating: 1H 2026 investment reached $31B across 1,101 deals, with Q2 representing the strongest quarter in the dataset and marking the best back-to-back quarterly performance of the current cycle.

• Capital allocation remains barbelled: Investors are backing select early-stage companies while concentrating substantial capital into later-stage, momentum-driven rounds, even as first-time financings remain difficult.

• Round structures are beginning to normalize: After the mega-round-heavy environment of 2024–2025, improving risk appetite and stronger M&A activity are supporting a partial return to more traditional round sizes and tighter syndicates, although capital remains concentrated in larger financings.

• Biopharma continues to dominate healthcare venture: Biopharma captured 50% of healthcare venture dollars in 1H 2026, reinforcing its position as the largest recipient of healthcare venture capital.

Recent Biotech IPO Tracker

Please see the detailed report below:

Biotech Monthly Insights September 2026 V2026

1.75MB ∙ PDF file

Download

Download

Specialty EHRs are evolving beyond documentation systems into broader platforms that combine clinical workflows, administrative functions, financial operations, AI, and data monetization.

Horizontal EHRs are built around standardized, multi-specialty workflows. That model works poorly in areas such as oncology, ophthalmology, gastroenterology, and behavioral health, where providers manage more complex clinical pathways, imaging, procedures, specialty billing, and disease-specific data.

That complexity creates room for vertical software. Specialty EHR vendors can embed themselves more deeply into day-to-day practice operations, creating higher switching costs and stronger opportunities to expand into adjacent products.

Specialty EHRs Are Gaining Share

• Horizontal EHRs leave workflow gaps: Specialty practices need purpose-built clinical, imaging, reporting, and billing workflows that generic systems often cannot support efficiently.

• Administrative complexity drives deeper adoption: Complex coding, reimbursement, registries, imaging, and patient workflows push specialty EHRs beyond recordkeeping into broader operating platforms.

• Fragmentation is driving consolidation: Providers use multiple point solutions across clinical and financial workflows, creating demand for integrated specialty platforms.

Data Is Becoming a Strategic Asset

Specialty EHR vendors also accumulate longitudinal, disease-specific datasets as they become embedded in clinical workflows.

That data can support clinical research, registries, trial matching, RWD/RWE, and life-sciences partnerships, creating an additional monetization layer beyond provider software budgets.

Specialty EHR Market Segments

Select M&A Transactions in Past 12 Months

Revenue Streams & Investor Perspectives

Specialty EHR vendors increasingly use the core EHR as a land product, then expand monetization across higher-value workflows, AI, RCM, payments, and data, increasing ARPU, customer stickiness, and strategic value.

• Core software: EHR SaaS, specialty modules, and practice-management software generate recurring revenue, high gross margins, and strong customer retention.

• AI & automation: Ambient documentation, coding, and clinical decision support create incremental subscription or usage-based revenue while expanding ARPU.

• Financial workflows: RCM, billing, and payments let vendors participate directly in practice economics, with RCM potentially generating 2–7% of collections.

• Data monetization: RWD/RWE licensing opens access to pharma and biotech budgets and can generate 85%+ gross margins.

Please see the detailed report below: